Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00431015
Recruitment Status : Completed
First Posted : February 2, 2007
Last Update Posted : December 10, 2012
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.

Brief Summary:
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also evaluate the anti-tumor activity of IPI-504.

Condition or disease Intervention/treatment Phase
Lung Cancer Drug: IPI-504 Phase 1 Phase 2

Detailed Description:
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in maintaining the proper folding, function and viability of various "client proteins". Many of the client proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. This clinical trial will study the effects of IPI-504 in a molecularly defined sub-group of patients who carry client proteins found in non-small cell lung cancer.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed and / or Refractory Stage IIIb (With Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients
Study Start Date : January 2007
Actual Primary Completion Date : August 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Intervention Details:
    Drug: IPI-504
    IV Hsp90 inhibitor

Primary Outcome Measures :
  1. Determine potential anti-tumor activity of IPI-504 in molecularly defined sub-groups of patients by RECIST criteria [ Time Frame: Every 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or pericardial effusion) or Stage IV NSCLC
  • Measurable disease by RECIST criteria.

Exclusion Criteria:

  • Treatment for NSCLC with any approved or investigational product within 2 weeks of the start of IPI-504 treatment for any small molecule therapy; within 4 weeks of the start of IPI-504 treatment for any biologic or any conventional chemotherapy.
  • Inadequate hematologic or renal or hepatic function
  • Previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00431015

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Connecticut
Yale Comprehensive Cancer Center
New Haven, Connecticut, United States, 06519
United States, Florida
Mount Sinai Comprehensive Cancer Center
Miami, Florida, United States, 33140
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Georgia
Medical College of Georgia
Augusta, Georgia, United States, 30912
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, Texas
Mary Crowley Cancer Research Centers - Medical City
Dallas, Texas, United States, 75201
Mary Crowley Cancer Research Centers - Baylor
Dallas, Texas, United States, 75246
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Infinity Pharmaceuticals, Inc.
Principal Investigator: Lecia Sequist, MD Massachusetts General Hospital

Responsible Party: Infinity Pharmaceuticals, Inc. Identifier: NCT00431015     History of Changes
Other Study ID Numbers: IPI-504-03
First Posted: February 2, 2007    Key Record Dates
Last Update Posted: December 10, 2012
Last Verified: December 2012

Keywords provided by Infinity Pharmaceuticals, Inc.:
Lung Cancer
Cancer of the lung
Non-small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms